vs
Side-by-side financial comparison of FULTON FINANCIAL CORP (FULT) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
FULTON FINANCIAL CORP is the larger business by last-quarter revenue ($336.2M vs $281.3M, roughly 1.2× Guardant Health, Inc.). FULTON FINANCIAL CORP runs the higher net margin — 28.2% vs -45.7%, a 73.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 4.2%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 0.2%).
Fulton Financial Corporation is an American regional financial services holding company, headquartered in Lancaster, Pennsylvania.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
FULT vs GH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $336.2M | $281.3M |
| Net Profit | $94.8M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | -43.0% |
| Net Margin | 28.2% | -45.7% |
| Revenue YoY | 4.2% | 39.4% |
| Net Profit YoY | 1.9% | -15.8% |
| EPS (diluted) | $0.55 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.2M | — | ||
| Q4 25 | $336.0M | $281.3M | ||
| Q3 25 | $334.6M | $265.2M | ||
| Q2 25 | $324.1M | $232.1M | ||
| Q1 25 | $318.4M | $203.5M | ||
| Q4 24 | $319.6M | $201.8M | ||
| Q3 24 | $317.7M | $191.5M | ||
| Q2 24 | $334.7M | $177.2M |
| Q1 26 | $94.8M | — | ||
| Q4 25 | $99.0M | $-128.5M | ||
| Q3 25 | $100.5M | $-92.7M | ||
| Q2 25 | $99.2M | $-99.9M | ||
| Q1 25 | $93.0M | $-95.2M | ||
| Q4 24 | $68.6M | $-111.0M | ||
| Q3 24 | $63.2M | $-107.8M | ||
| Q2 24 | $95.0M | $-102.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | — | — | ||
| Q4 25 | 35.7% | -43.0% | ||
| Q3 25 | 38.2% | -37.3% | ||
| Q2 25 | 37.8% | -45.9% | ||
| Q1 25 | 36.1% | -54.6% | ||
| Q4 24 | 27.0% | -62.4% | ||
| Q3 24 | 25.1% | -61.3% | ||
| Q2 24 | 30.8% | -56.8% |
| Q1 26 | 28.2% | — | ||
| Q4 25 | 29.5% | -45.7% | ||
| Q3 25 | 30.0% | -35.0% | ||
| Q2 25 | 30.6% | -43.0% | ||
| Q1 25 | 29.2% | -46.8% | ||
| Q4 24 | 21.5% | -55.0% | ||
| Q3 24 | 19.9% | -56.3% | ||
| Q2 24 | 28.4% | -57.9% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.53 | $-1.01 | ||
| Q3 25 | $0.53 | $-0.74 | ||
| Q2 25 | $0.53 | $-0.80 | ||
| Q1 25 | $0.49 | $-0.77 | ||
| Q4 24 | $0.36 | $-0.90 | ||
| Q3 24 | $0.33 | $-0.88 | ||
| Q2 24 | $0.52 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $3.5B | $-99.3M |
| Total Assets | $32.2B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $-99.3M | ||
| Q3 25 | $3.4B | $-354.5M | ||
| Q2 25 | $3.3B | $-305.5M | ||
| Q1 25 | $3.3B | $-250.8M | ||
| Q4 24 | $3.2B | $-139.6M | ||
| Q3 24 | $3.2B | $-60.1M | ||
| Q2 24 | $3.1B | $-1.6M |
| Q1 26 | $32.2B | — | ||
| Q4 25 | $32.1B | $2.0B | ||
| Q3 25 | $32.0B | $1.3B | ||
| Q2 25 | $32.0B | $1.3B | ||
| Q1 25 | $32.1B | $1.3B | ||
| Q4 24 | $32.1B | $1.5B | ||
| Q3 24 | $32.2B | $1.5B | ||
| Q2 24 | $31.8B | $1.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $304.5M | $-26.4M | ||
| Q3 25 | $116.1M | $-35.4M | ||
| Q2 25 | $91.7M | $-60.3M | ||
| Q1 25 | $703.0K | $-62.7M | ||
| Q4 24 | $416.6M | $-64.5M | ||
| Q3 24 | $-22.0M | $-51.1M | ||
| Q2 24 | $157.8M | $-94.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-54.2M | ||
| Q3 25 | — | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 6.07× | — | ||
| Q3 24 | -0.35× | — | ||
| Q2 24 | 1.66× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FULT
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
